AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02550054
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
Trial: NCT01051778
Drug: Heparin calcium5,000 U twice daily plus low dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
Trial: NCT02072200
Drug: Lodotra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
Trial: NCT03778671
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive Levobupivacaine 5% + 1 µg/kg fentanyl
Trial: NCT02647866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT00881608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 capsule daily for five days
Trial: NCT04559113
Drug: Methylprednisolone Injectable Product
RxNorm normalized name: methylprednisolone Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. 0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~2. Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day.
Trial: NCT01872611
Drug: Nepafenac Ophthalmic Suspension, 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01872611
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
Trial: NCT04386447
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~* Oxygen supply or non-invasive ventilation to target peripheral blood saturation \> 94%~* Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~* Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~* Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~* Prophylaxis for deep vein thrombosis~* Steroids are not routinely recommended but may be considered in selected patients.
Trial: NCT01537172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
Trial: NCT00660452
Drug: Staloral
RxNorm normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Alor]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with Staloral dust mites solution
Trial: NCT02519556
Drug: Probiatop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
Trial: NCT02519556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
Trial: NCT05266261
Drug: Ibandronate Oral Tablet
RxNorm normalized name: ibandronate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of ibandronate + 24,000 IU of cholecalciferol
Trial: NCT00434252
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion on the first day of each 3-week cycle
Trial: NCT00066456
Drug: Chemosensitization/Potentiation Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02733419
Drug: Optimized background antiretroviral regimen (OB)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.
Trial: NCT02868944
Drug: control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03099785
Drug: Placebo t.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet
Trial: NCT01515358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01515358
Drug: LY3000328
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01822821
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
Trial: NCT01822821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
Trial: NCT02806895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01235585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses, once a day for 52 weeks
Trial: NCT00618501
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00618501
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00618501
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00618501
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01067391
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet administered once per study protocol
Trial: NCT01363661
Drug: Coruno
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine 16 mg tablet, per os, once a day
Trial: NCT03276143
Drug: BAY1213790
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of BAY1213790 administered as intravenous infusion
Trial: NCT03345797
Drug: Testosterone Nasal Gel [Natesto]
RxNorm normalized name: testosterone Nasal Gel [Natesto]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal gel containing 4.5% w/w testosterone
Trial: NCT00163592
Drug: Tissucol®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01363661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (16 mg tablet, per os; once-daily)
Trial: NCT02606461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02556866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01612013
Drug: Intravenous NAC plus saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Trial: NCT01612013
Drug: NAC plus saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
Trial: NCT03635788
Drug: Standard of Care (SOC) Oral ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)
Trial: NCT03635788
Drug: Oral RPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPV 25 mg tablets
Trial: NCT03635788
Drug: RPV-LA Loading Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle
Trial: NCT03635788
Drug: RPV-LA Maintenance Dose
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
Trial: NCT03635788
Drug: CAB-LA Maintenance Dose
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
Trial: NCT01498874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
Trial: NCT00365417
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m\^2 IV every 21 days x 4 cycles
Trial: NCT00365417
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m\^2 IV every 21 days x 4 cycles
Trial: NCT00365417
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Following clinical response assessment, 650 mg/m\^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
Trial: NCT04274179
Drug: Absence epilepsy medications
RxNorm normalized name: BRACELET,MEDICAL ALERT EPILEPSY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At neurologist's discretion. \*OF NOTE\< THIS ARM IS COMPLETED
Trial: NCT03150368
Drug: ModraDoc006/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Trial: NCT01365338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT00851591
Drug: fenugreek
RxNorm normalized name: fenugreek
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules 3 times per day with a full glass of water each dose for 7 days
Trial: NCT00851591
Drug: Placebo (Psyllium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules 3 times a day with a full glass of water each dose for 7 days
Trial: NCT01313637
Drug: GSK573719/GW642444 125/25mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125/25mcg
Trial: NCT06004960
Drug: [14C]CCX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01313637
Drug: GSK573719 125mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125mcg
Trial: NCT01313637
Drug: GW642444 25mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mcg
Trial: NCT01313637
Drug: Placebo only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03518684
Drug: Natalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping
Trial: NCT01304147
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of saline intranasal
Trial: NCT03416127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.
Trial: NCT04332276
Drug: A-dopamine
RxNorm normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days.
Trial: NCT04332276
Drug: optimized oral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will received his usual dopaminergic treatment.
Trial: NCT02222636
Drug: Normal saline,1 milliliter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline,1 milliliter, 20 minutes before anaesthetic induction
Trial: NCT02222636
Drug: Anesthesia maintenance, 2%~3% sevoflurane,fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
Trial: NCT02630888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
Trial: NCT03271697
Drug: Astragalus Membranaceus
RxNorm normalized name: Astragalus membranaceus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
Trial: NCT03271697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as a comparator comparing with AM group
Trial: NCT02054156
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
Trial: NCT02054156
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
Trial: NCT02054156
Drug: Tobramycin solution for inhalation
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
Trial: NCT03873532
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID, one dose each in the morning and evening, with a total dose of 2500 mg/m2 per day) for 2 weeks followed by 1 week of drug interruption. Each course of treatment will last 3 weeks. Capecitabine tablets should be swallowed with water within 30 minutes after a meal.
Trial: NCT00516646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bid
Trial: NCT00706797
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02715531
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 200 mg/m\^2 L-isomer form or 400 mg/m\^2 D,L-racemic form will be administered IV over 120 (± 15) minutes, q2w.
Trial: NCT02715531
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m\^2) twice daily on Days 1-4 of a 21-day cycle.
Trial: NCT03537287
Drug: 17 alpha hydroxyprogestrone caproate
RxNorm normalized name: 17-alpha-hydroxy-progesterone caproate
DrugBank: Hydroxyprogesterone caproate (DB06789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg of 17 alpha hydroxyprogestrone caproate weekly
Trial: NCT01746680
Drug: Tacrolimus with Methotrexate
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 1 mg for 0\~week4, 2mg for week4\~week8, 3mg for week8\~week24 with MTX ≤20mg/week
Trial: NCT01586325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo administered once daily as monotherapy for 5 days.
Trial: NCT03621553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic ergocalciferol 50,000 units
Trial: NCT02423408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT01687699
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01518257
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
Trial: NCT00512408
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04100473
Drug: Inhaled Human Insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance 501 administered using the Dance 501 Inhaler
Trial: NCT01102478
Drug: losartan potassium / hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg / 25 mg tablet
Trial: NCT01287065
Drug: Placebo AM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation powder
Trial: NCT01287065
Drug: Placebo PM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation powder
Trial: NCT03227796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion
Trial: NCT00537485
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal application, 1 time per day
Trial: NCT04870164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One administration at day 1 by infusion.
Trial: NCT00537485
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal application, 1 time per day
Trial: NCT00908232
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
Trial: NCT01148966
Drug: aminolevulinic acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00448864
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01600703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral, single dose
Trial: NCT01371201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 37.5 mg per day
Trial: NCT00185172
Drug: olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
Trial: NCT03217409
Drug: Rosuvastatin+Ezetimibe
RxNorm normalized name: ezetimibe / rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5mg+Ezetimibe 10mg
Trial: NCT03217409
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5Mg Tablet
Trial: NCT00486044
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tablet each night for one month, then 80 mg for 8 months
Trial: NCT00486044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching tablet each night for 9 months
Trial: NCT02737722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no